Zydus Cadila and Turkey based healthcare firm, Eczacibasi Ilac Pazarlama have signed an agreement for marketing biotech products in the Turkish market.

Cadila Healthcare has said in a BSE filing that the collaboration agreement involves the import of biosimilars that are currently unavailable in Turkey, especially for the treatment of cancer.

It added that the pact also paves way for a long term collaboration to produce and launch new products in the market.

However, the financial details of the agreement has not been disclosed by the company.

Read EquityPandit’s Technical Analysis on Nifty Pharma